6 There is no evidence that any of these regimens are superior to one another. Mogamulizumab is a monoclonal antibody that targets CCR4 expressed in neoplastic cells in ∼90% of ATL cases and mutated in 26%. This expression has been associated with cutaneous manifestations and poor prognosis...